tiprankstipranks
Trending News
More News >
Creative Medical Technology Holdings, Inc. (CELZ)
:CELZ
US Market
Advertisement

Creative Medical Technology Holdings (CELZ) Drug Pipeline

Compare
195 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Celz-201-Ddt
Degenerative Disc Disease, Chronic Low-Back Pain
Phase I/II
Recruiting
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Sep 17, 2023
Control Group, Celz-201 Administration
Type 1 Diabetes, Diabetes Mellitus, Type 1
Phase I/II
Recruiting
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
Nov 07, 2022

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Creative Medical Technology Holdings, Inc. (CELZ) have in its pipeline
      CELZ is currently developing the following drugs: Celz-201-Ddt, Control Group, Celz-201 Administration. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis